Monitor upcoming clinical data readouts for ABS-1230, particularly pivotal trial results and regulatory milestones, as these will be key catalysts for JAZZ stock. The $820M upfront payment is a significant cash outlay, so watch for any impact on Jazz's balance sheet or future financing needs.
Price Chart
Executive Summary
Jazz Pharmaceuticals completed the acquisition of Actio Biosciences for $820 million upfront, adding ABS-1230, a clinical-stage potential first-in-class precision therapy for KCNT1-related epilepsy. The deal strengthens Jazz's epilepsy pipeline and diversifies its rare disease portfolio, though ABS-1230 remains in early clinical development with regulatory and commercial risks ahead.
Key Facts
- Jazz completed the acquisition of Actio Biosciences for $820 million upfront.
- ABS-1230 is a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy.
- ABS-1230 has received Fast Track, Rare Pediatric Disease, and Orphan Drug Product designations from the FDA.
- In an early clinical proof-of-concept trial, children with KCNT1-related epilepsy who received ABS-1230 experienced meaningful seizure reductions.
- Actio spun out a new privately-held entity for non-ABS-1230 programs, with Jazz receiving a minority stake.
- The acquisition was completed through a merger of a Jazz subsidiary with and into Actio.
Financial Impact
$820 million upfront cash consideration for the acquisition of Actio Biosciences.
Risk Factors
- ABS-1230 is still in clinical development; pivotal trial failure or regulatory setbacks could impair the deal's value.
- The $820 million upfront cost is substantial and may pressure Jazz's cash position or require future capital raises.
- Integration risks and potential delays in advancing ABS-1230 through the pipeline.
- Competing therapies for KCNT1-related epilepsy could emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (JAZZ) — Batch item 1 | 0001628280-26-061978 |
| Exhibit: exhibit991closingpr.htm | 0001628280-26-061978 |
| Document: 0001628280-26-061978-index-headers.html | 0001628280-26-061978 |
| Document: 0001628280-26-061978-index.html | 0001628280-26-061978 |
| Document: 0001628280-26-061978.txt | 0001628280-26-061978 |
| 8-K Filing (JAZZ) — Batch item 6 | 0001628280-26-061978 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | Press Release | $213.76 $211.97 | ▼ −0.84% | ▼ −1.36% | $210.99 (−1.30%) |
Oct 9, 2026 17d ago | 8-K | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 8, 2026 17d ago | 144 | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 6, 2026 19d ago | 144 | $231.19 $222.45 | ▼ −3.78% | ▼ −3.36% | $210.99 (−8.74%) |
Oct 1, 2026 24d ago | 144 | $235.67 $236.04 | ▲ +0.16% | ▼ −0.52% | $210.99 (−10.47%) |
Sep 15, 2026 5w ago | 8-K | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 14, 2026 5w ago | Insider Cluster | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 10, 2026 6w ago | Insider Cluster | $245.80 $245.87 | ▲ +0.03% | ▲ +0.47% | $210.99 (−14.16%) |
Sep 2, 2026 7w ago | Insider Cluster | $247.57 $246.81 | ▲ +0.30% | ▼ −0.08% | $210.99 (+14.78%) |
Aug 31, 2026 7w ago | 144 | $243.71 $245.57 | ▲ +0.76% | ▲ +0.32% | $210.99 (−13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers